# OnCo record secore-cdx-hla (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/secore-cdx-hla/>
  a schema:MedicalTest ;
  onco:kind "drug" ;
  schema:identifier "secore-cdx-hla" ;
  schema:name "SeCore CDx HLA Sequencing System"@en ;
  schema:description "The blood test that checks a person's tissue type (HLA-A*02) before tebentafusp for uveal melanoma or afamitresgene autoleucel for synovial sarcoma."@en ;
  schema:url <https://onco.cc/drugs/secore-cdx-hla/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools>, <https://www.thermofisher.com/onelambda/us/en/about-us.html> ;
  onco:status "approved" ;
  onco:tag "test" ;
  onco:modality "HLA sequencing companion diagnostic test (whole blood)" ;
  schema:alternateName "SeCore CDx HLA Sequencing System" ;
  onco:approval "US 2022: Companion diagnostic for tebentafusp in uveal melanoma (HLA-A*02:01)", "US 2024: Companion diagnostic for afamitresgene autoleucel in synovial sarcoma (eligible HLA-A*02 alleles)" ;
  onco:related <https://onco.cc/drugs/mage-a4-ihc-1f9-pharmdx/>, <https://onco.cc/biomarkers/hla-a-02-01/> ;
  onco:cancers <https://onco.cc/cancers/uveal-melanoma/>, <https://onco.cc/cancers/synovial-sarcoma/> ;
  onco:technologies <https://onco.cc/technologies/companion-diagnostic/> ;
  onco:targets <https://onco.cc/targets/hla-a/> ;
  onco:drugs <https://onco.cc/drugs/tebentafusp/>, <https://onco.cc/drugs/afamitresgene-autoleucel/> ;
  onco:companies <https://onco.cc/companies/one-lambda/> ;
  onco:terms <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/companion-diagnostic-term/> .